肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CPP：吉非替尼可清除转移性乳腺癌患者体内循环肿瘤细胞

2014-05-05 秀荣 医学论坛网

吉非替尼乳腺癌肿瘤
关注

希腊学者研究发现，转移性乳腺癌（MBC）患者中，难治性循环肿瘤细胞（CTC）可被吉非替尼清除；EGFR表达在CTC中作为一种有效、特异性靶向CTC的潜在生物标记应该被进一步验证。论文2014年4月1日在线发表于《癌症化疗与药理学》（Cancer Chemotherapy and Pharmacology）杂志。 研究对象为17例体内可检测到CTC的MBC患者。他们在结束先前治疗之后每天被口服给予

希腊学者研究发现，转移性乳腺癌（MBC）患者中，难治性循环肿瘤细胞（CTC）可被吉非替尼清除；EGFR表达在CTC中作为一种有效、特异性靶向CTC的潜在生物标记应该被进一步验证。论文2014年4月1日在线发表于《癌症化疗与药理学》（Cancer Chemotherapy and Pharmacology）杂志。

研究对象为17例体内可检测到CTC的MBC患者。他们在结束先前治疗之后每天被口服给予250mg吉非替尼；在进行抗-细胞角质蛋白（A45-B/B3）和抗CD45或抗EGFR抗体双染色之后，使用免疫荧光显微技术对CTC进行检测。

结果为，在第一个和第二个治疗周期后，分别有11例(64.7 %)和12例患者(70.6 %)的CTC计数的中位值下降了96.4%和94.1 %，总CTC数量两次分别降低了73%和44 %。在9例EGFR(+)/CK(+) CTCs患者中，吉非替尼使EGFR(+)和EGFR(−) CTC的数量都降低了。在第三个治疗周期后，检测出的CTC大部分是EGFR(−)。在2例CTC数量持续下降的患者中，发现他们的PFS分别为16.0和19.0个月，其中一人的这种情况与临床客观反应相关。

原始出处：


Kalykaki A1, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V.Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.Cancer Chemother Pharmacol. 2014 Apr;73(4):685-93. doi: 10.1007/s00280-014-2387-y. Epub 2014 Feb 4.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1312893, encodeId=41de1312893e0, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386114, encodeId=ab9113861144b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570919, encodeId=746015e09193d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580942, encodeId=d79c15809420d, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
    2014-05-07 hmwwww

    #肿瘤细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1312893, encodeId=41de1312893e0, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386114, encodeId=ab9113861144b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570919, encodeId=746015e09193d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580942, encodeId=d79c15809420d, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
    2014-05-07 1249842em09(暂无昵称)

    #转移性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1312893, encodeId=41de1312893e0, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386114, encodeId=ab9113861144b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570919, encodeId=746015e09193d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580942, encodeId=d79c15809420d, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
    2014-05-07 hanhaisha2013

    #乳腺癌患者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1312893, encodeId=41de1312893e0, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386114, encodeId=ab9113861144b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570919, encodeId=746015e09193d, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580942, encodeId=d79c15809420d, content=<a href='/topic/show?id=183c5045ed0' target=_blank style='color:#2F92EE;'>#循环肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50457, encryptionId=183c5045ed0, topicName=循环肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d2016667446, createdName=thinkibmz_44722599, createdTime=Wed May 07 07:57:00 CST 2014, time=2014-05-07, status=1, ipAttribution=)]
    2014-05-07 thinkibmz_44722599

    #循环肿瘤细胞#

    0

相关资讯

JCO：吉非替尼对完全切除的非小细胞肺癌无临床获益（NCIC CTG BR19研究）

研究背景：目前肺癌仍是全球发病最高的肿瘤类型，它也成为与癌症相关的男性和女性首要死亡因素。非小细胞肺癌(NSCLC)约占所有肺部肿瘤的85%。在2002年NCIC CTG BR19 (CTSUBR19)研究启动时，以铂制剂为基础的辅助化疗尚未广泛付诸应用，当时I期患者的5年生存率为60%至70%，II期患者则降低至40%。尽管部分研究表明，辅助化疗具有一定疗效，但当时并未将其作为常规的治疗手段，并

Clin Oncol：吉非替尼改善非小细胞肺癌预后

　　我国学者近期发表于《临床肿瘤学》（Clin Oncol）杂志的一项研究表明，与全身化疗相比，吉非替尼一线治疗可延长表皮生长因子受体（EGFR）突变非小细胞肺癌患者的无进展生存期（PFS），并改善肺腺癌患者的总生存状况。 　　为了确定吉非替尼对既往未接受化疗的晚期非小细胞肺癌的疗效，研究者进行了一项对于随机对照临床试验的荟萃分析。研究者搜索了Medline、Embase、Cochra

ASCO 2013：培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼

背景： 培美曲塞或吉非替尼为东亚地区晚期非鳞NSCLC患者二线治疗的常规治疗手段。CTONG 0806研究为一项多中心、随机对照、开放标签的II期临床试验，该试验针对无EGFR突变的晚期NSCLC患者，旨在对培美曲塞与吉非替尼用于二线治疗时的疗效进行对比考察。 方法：本研究招募对象为局部晚期或转移性非鳞NSCLC患者，患者此前曾接受过铂制剂为基础的化疗，且第18-21外显子不存在EGFR突变。患

ASCO 2011: 埃克替尼耐受性优于吉非替尼

　ASCO 2011报道：Sun等的一项研究报告表明，在先前接受过一种或两种化疗药物治疗非小细胞肺癌（NSCLC）患者中，埃克替尼疗效与吉非替尼相似，但前者耐受性优于后者。 　　一线或二线化疗后疾病进展的NSCLC患者被随机分为埃克替尼（150 mg每日3次）或吉非替尼治疗组（250 mg 每日1次）。主要终点是无进展生存期（PFS）。次要终点是总生存期（OS）、客观缓解率（ORR）、至肿瘤进